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Abstract
Background: Although psoriatic arthritis is complex and involves multiple domains, recent advances in treatments
have made remission or near-remission of most symptoms a potentially achievable goal for many patients.
We sought to evaluate whether achieving minimal disease activity (MDA) criteria represented meaningful
improvement from the patient perspective.
Methods: Data were combined from two randomized, multinational, 24 week clinical studies of ixekizumab, a
high-affinity monoclonal antibody selectively targeting interleukin-17A, in biological drug-naïve or experienced
adults. MDA required 5 of 7 of: tender joint count ≤1; swollen joint count ≤1; Psoriasis Area and Severity Index total
score≤ 1 or body surface area≤ 3%; patient’s assessment of pain visual analogue scale (VAS) ≤15; patient’s global
assessment of disease activity VAS ≤20; Health Assessment Questionnaire Disability Index ≤0.5; and tender entheseal
points≤ 1. MDA responders and non-responders were compared for mean change from baseline on the 36-Item Short
Form Health Survey (SF-36), European Quality of Life 5 Dimension 5 Level Health Questionnaire (EQ-5D-5 L); EQ-5D-5 L
VAS; and Work Productivity and Activity Impairment–Specific Health Problem (WPAI-SHP) questionnaire.
Results: MDA responders had significantly greater improvements versus non-responders in each SF-36 domain and in
the SF-36 physical summary score; improvements were also greater in the EQ-5D-5 L and EQ-5D-5 L VAS, and in 3 of
the 4 WPAI-SHP domains. MDA responders were more likely to achieve minimal clinically important differences than
non-responders.
Conclusion: These findings support MDA response as being strongly associated with achieving improved disease
status based on measures of patient reported health-related quality of life and productivity.
Trial registration: SPIRIT-P1, NCT01695239, First Posted: September 27, 2012; and SPIRIT-P2, NCT02349295, First
Posted: January 28, 2015.
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Background
Psoriatic arthritis (PsA) is an inflammatory musculoskel-
etal disease with heterogeneous clinical manifestations
and significant impact on daily activities [1]. Approxi-
mately 80% of patients with PsA have psoriasis before
manifesting arthritis, with the musculoskeletal disease de-
veloping on average 10 years after the onset of skin disease
[2]. Clinical manifestations of PsA are frequently associ-
ated with substantial decrements in health status, includ-
ing physical, emotional, and psychosocial functional
disability and reduced quality of life [3, 4]. Recently, the
morbidity associated with non-musculoskeletal as well as
the musculoskeletal features of PsA has been better recog-
nized [5], and led to the development of a number of
composite endpoints that include evaluation of the PsA
patient across the range of symptoms [6–8].
The availability of novel treatments with the potential
to treat to remission or near remission has led to a para-
digm shift in the therapeutic management of PsA, with
treatment targets now favoring low absolute levels of
disease activity across multiple disease domains rather
than relative improvements [6, 9]. Of the various
composite measures currently available, minimal disease
activity (MDA) addresses this shift and is realistic for
clinical implementation [10, 11]. MDA response has
been longitudinally validated in the effect of TIght
COntrol of inflammation in early Psoriatic Arthritis
(TICOPA) study, a randomized treatment strategy
clinical trial [12, 13]. Tight control was shown to result
in more patients achieving the primary endpoint of
American College of Rheumatology 20% (ACR20), and
resulted in a greater median improvement in Psoriatic
Arthritis Quality of Life (PsAQoL), a PsA specific quality
of life measure. Achievement of MDA in PsA patients
has also been shown to have prognostic value for
long-term outcomes, including improved physical func-
tioning and decrease in radiographic progression in both
interventional clinical trials and observational cohorts [11,
14, 15]. It is important to understand how these improve-
ments translate to patient-recognized benefit in order to
further validate MDA as a potential composite endpoint
for future PsA randomized controlled trials (RCTs).
The efficacy and safety of ixekizumab, a high-affinity
monoclonal antibody selectively targeting interleukin-17A,
have been evaluated in 2 phase III RCTs in patients with
PsA. A significantly higher proportion of ixekizumab versus
placebo patients achieved the primary endpoint at 24 weeks
of ACR20, as well as numerous other efficacy endpoints, in
both the biologic treatment-naïve [16, 17] and biologic ex-
perienced [18] PsA populations. The objective of the
present study was to evaluate whether achievement of
MDA was associated with improvements in outcomes im-
portant to PsA patients including generic health-related
quality of life (HRQoL) and productivity.
Methods
Study design
Data were analyzed from an integrated database of 2 ran-
domized, multinational, double-blind, placebo-controlled
phase III trials investigating the efficacy and safety of
ixekizumab for patients with active PsA. SPIRIT-P1
(NCT01695239) evaluated biologic disease modifying
anti-rheumatoid drug (DMARD) naïve patients during a
double-blind study period between January 2013 and
December 2014. Patients in SPIRIT-P2 (NCT02349295)
were conventional synthetic DMARD (csDMARD)
experienced and previously had an inadequate response or
were intolerant to tumor necrosis factor inhibitors; the
double-blind study period occurred between March 2015
and September 2016. Patients were randomized to placebo
(n = 224) or 80 mg ixekizumab every 4 weeks (IXEQ4W,
n = 229) or every 2 weeks (IXEQ2W, n = 226) after a
160 mg starting dose. SPIRIT-P1 also included an adali-
mumab reference arm; however, data from the adalimu-
mab arm were not analyzed in the present integrated
study since there was no adalimumab arm in the
SPIRIT-P2 trial.
Eligible patients were ≥ 18 years of age with a diag-
nosis of PsA for ≥6 months and fulfilled the Classifi-
cation Criteria for Psoriatic Arthritis (CASPAR) [19].
Additional eligibility requirements for both studies in-
cluded at least 3 of 68 tender joints, at least 3 of 66
swollen joints, and plaque psoriasis (current or per-
sonal history). Principal exclusion criteria were history
of most types of malignant disease; recent infection
requiring hospitalization or antibiotic treatment; posi-
tive test for hepatitis B, hepatitis C, or human im-
munodeficiency virus; or liver function or hematology
test results outside of predefined limits. Primary study
results and additional details on study populations
and designs have been published previously [16, 18].
Assessments
MDA was achieved if 5 of 7 criteria were met: tender joint
count ≤1; swollen joint count ≤1; Psoriasis Area and
Severity Index (PASI) total score ≤ 1 or body surface area ≤
3%; patient’s assessment of pain visual analogue scale
(VAS) ≤15 mm; patient’s global assessment of disease
activity VAS ≤20 mm; Health Assessment Questionnaire
(HAQ) Disability Index ≤0.5; and tender entheseal
points ≤ 1 (assessed by the Leeds Enthesitis Index).
The primary instrument evaluated for correlation
with MDA status was the 36-Item Short Form Health
Survey (SF-36; higher scores indicate better function-
ing), with analyses focused on the 8 subscales of
physical functioning, role physical, bodily pain,
general health, vitality, social functioning, role emo-
tional, and mental health. Data are also presented for
the Physical Component Summary (PCS) and Mental
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Component Summary (MCS). Additional measures
assessed include: The European Quality of Life 5 Di-
mension 5 Level Health Questionnaire (EQ-5D-5 L)
assessing the domains of mobility, self-care, usual ac-
tivities, pain/discomfort, and anxiety/depression, rat-
ing each on a scale of 1 to 5 as having “no problems,
slight problems, moderate problems, severe problems,
and extreme problems”); the EQ-5D VAS (0–100
scale; higher scores indicate better health); and the
Work Productivity and Activity Impairment–Specific
Health Problem (WPAI-SHP), assessing percentage of
absenteeism, percentage of presenteeism, overall work
impairment, and percentage of activity impairment
outside work; higher scores indicate higher impair-
ment). Scores for the EQ-5D-5 L were converted to a
health state index score [20]; the UK algorithm was
used to produce a patient-level index score between
− 0.59 and 1.0 (continuous variable) using values
given for the November 2014 crosswalk value sheet.
Minimum clinically important differences (MCID)
were defined as a change from baseline for the SF-36
PCS and MCS scores of ≥2.5-points and for the SF-36
domain scores of ≥5 points [21, 22]; for the EQ-5D-5 L
health index score of ≥0.05 points [23]; and for the
EQ-5D VAS of ≥10-points [24].
Statistical analyses
The primary study endpoint was assessed at 24 weeks;
however, patients were assessed at 16 weeks for inad-
equate response based on fulfilling specific blinded pre-
defined criteria for change in either tender joint count
or swollen joint count from baseline. This analysis ex-
cludes inadequate responders at Week 16 and patients
who discontinued before Week 24. Data for patients in
the placebo and both ixekizumab arms from both RCTs
comprise the integrated database used for the present
analyses.
Continuous (change from baseline) analyses used a
one-way ANOVA where MDA responder status is the
only factor in the model. For categorical data (MCID),
analyses used a chi-square if the expected value for each
cell was 4 or higher; otherwise, a Fisher’s exact was used.
No adjustments were made for missing data.
Results
The overall study population included 679 patients, with
224 randomized to placebo, 226 randomized to
IXEQ2W, and 229 randomized to IXEQ4W; participants
who were classified as inadequate responders at Week
16 were excluded from the analysis population at Week
24 (Week 24 analysis population, N = 483). At baseline,
mean age was 50.8 years; 53.8% of patients were female;
and patients identified predominately as white (93.4%;
Table 1). Mean (SD) time from PsA onset was 11.0 (9.0)
years, mean CASPAR total score was 4.4 (0.9), and mean
PASI total score among patients with current plaque
psoriasis was 6.2 (7.5). At baseline, 59.4% of patients
were csDMARD experienced and nearly half were cur-
rently receiving methotrexate (48.2%). MDA responders
compared to non-responders were younger and were
more likely to be male and have lower weight and body
mass index (BMI).
At baseline, SF-36 domain scores for patients who sub-
sequently met MDA responder criteria at 24 weeks were
significantly higher than those for MDA non-responders
for all domains (Fig. 1a; see Additional File 1: Table S1 for
p-values). Following treatment, MDA responders had
significantly greater improvements versus MDA
non-responders in each of the 8 SF-36 domains (Fig. 1b).
The magnitude of improvements for MDA responders
was greatest for the physically oriented domains (bodily
pain, role physical, and physical functioning; range of
mean [SD] from 27.4 [25.6] to 31.7 [22.3]), followed by
general health, vitality, and social functioning; range 15.8
[16.7] to 19.5 [26.9]), and was more modest, albeit still sig-
nificantly greater, versus non-responders for the role emo-
tional (12.7 [24.8]) and mental health (10.6 [20.1])
domains. In addition, the SF-36 PCS mean change from
baseline was significantly higher for MDA responders ver-
sus non-responders, while the difference for the MCS was
not statistically significant (Table 2).
Additional measures that improved more for MDA re-
sponders versus non-responders included the EQ-5D-5 L
Health State Index (0.20 [0.20] vs. 0.07 [0.20], respectively;
p < .001) and the EQ-5D VAS (22.5 [21.7] vs. 5.7 [22.4]; p
< .001). Most measures assessed on the WPAI-SHP (per-
centage of presenteeism, overall work impairment, and
percentage of activity impairment outside of work) also
showed significantly greater improvements among MDA
responders versus non-responders (all p < .001), although
the difference in percentage of absenteeism was not statis-
tically significant (p = .096;
In addition to comparisons based on mean changes
from baseline to 24 weeks, the percentage of patients
achieving MCID on the various measures was assessed
based on MDA response, as shown in Table 3. For the
SF-36 domains, significantly greater odds of achieving
MCID were seen for MDA responders versus non-re-
sponders for physical functioning, role physical, bodily
pain, and general health; odds ratio (OR) (95% confi-
dence interval) range 3.41 (2.14, 5.43) to 4.21 (2.55,
6.97), as well as for vitality; OR 2.60 (1.68, 4.04), and
social functioning; OR 1.94 (1.30, 2.87); all p < .001, but
not for role emotional or mental health. Participants
who entered MDA status were six times more likely to
achieve MCID in the SF-36 PCS score than
non-responders; OR 6.21, (3.76, 10.26); p < 0.001, while
no significant difference was seen in the SF-36 MCS
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score (p = 0.55) (Table 3). For the EQ-5D-5 L HSI and
EQ-5D VAS the proportions of patients achieving MCID
improvements were significantly greater for MDA re-
sponders versus non-responders (all p < .001).
Discussion
As PsA treatment paradigms evolve, clinical trials are in-
creasingly measuring multiple disease manifestations
and aspects of life impact. Although therapeutic options
are increasing, a significant number of PsA patients do
not achieve uniform improvements indicating an unmet
need for outcome prediction strategies to inform our
current approach to treatment. MDA has been identified
as an optimal state to aim for in treating PsA [25].
In the present study, we hypothesized that based on
reduced pain and physical symptoms, MDA responders
would experience greater improvements than non-re-
sponders in physical, emotional, and psychosocial out-
comes, including domains of importance to patients
such as the ability to work and impairment at home
[26]. Indeed, MDA responders demonstrated signifi-
cantly greater improvements than non-responders in all
SF-36 domains, with the greatest improvements in phys-
ical functioning, role physical, and bodily pain. A signifi-
cant improvement was also seen for the SF-36 PCS, but
not MCS, as discussed below. Significantly greater im-
provements were seen for MDA responders versus
non-responders in the EQ-5D-5 L Health State Index
and EQ-5D VAS, supporting the value of MDA response
as a predictor of health utility. MDA responders also had
significantly greater improvements versus non-responders
in presence at work, overall work impairment, and per-
centage of activity impairment outside of work, as
assessed by the WPAI-SHP instrument. Proportions of pa-
tients achieving MCID cutoffs were significantly greater in
MDA responders versus non-responders, with differences
seen for 6 of the 8 SF-36 domains (all domains except role
emotional and mental health), the SF-36 PCS, and for the
EQ-5D-5 L Health State Index and EQ-5D VAS.
A significant improvement was not seen for the SF-36
MCS in this study. Notably, the SF-36 summary scores
are calculated as a weighted sum of all 8 domains, but
for the MCS, the mental domains are weighted positively
and the physical domains negatively; given that the phys-
ical domains showed the greatest improvement with
MDA response, this may have prevented the detection
of an effect on the MCS. Indeed on further analysis, at
Week 24 all eight component scores showed signifi-
cantly greater improvement from baseline among MDA
responders versus nonresponders (data not shown), sug-
gesting that the negative weighting in MCS may be the
issue. Such inconsistencies have led to the recommenda-
tion that conclusions should not be drawn solely on PCS
and MCS scores without taking individual domain scores
into consideration [27].
Some differences were noted between the populations
of patients who became responders and those who did
not. At baseline, patients who became MDA responders
Table 1 Baseline characteristics by MDA responder (−R) or non-responder (-NR) status and overall
Measure MDA-R (N = 157) MDA-NR (N = 326) Total (N = 483) p-value
Age, mean (SD) 48.2 (13.7) 52.1 (10.8) 50.8 (12.0) 0.002
Female gender, n (%) 68 (43.3) 192 (58.9) 260 (53.8) 0.001
Race, n (%) 0.121
White 143 (91.1) 307 (94.5) 450 (93.4)
Asian 8 (5.1) 13 (4.0) 21 (4.4)
Other 6 (3.8) 5 (1.5) 11 (2.3)
Weight kg, mean (SD) 81.1 (17.3) 88.1 (21.2) 85.9 (20.3) < 0.001
BMI kg/m2, mean (SD) 27.7 (5.1) 31.0 (7.6) 30.0 (7.0) < 0.001
Time since PsA onset, mean years (SD) 10.5 (9.3) 11.2 (8.9) 11.0 (9.0) 0.51
Time since PsA diagnosis, mean years (SD) 7.7 (7.8) 8.5 (7.8) 8.2 (7.8) 0.63
CASPAR score, mean (SD) 4.4 (1.0) 4.4 (0.9) 4.4 (0.9) 0.96
Curr. enthesitis, n (%) 78 (50.0) 200 (61.7) 278 (57.9) 0.017
Curr. dactylitis, n (%) 47 (30.1) 63 (19.4) 110 (22.9) 0.027
Curr. psoriasis, n (%) 149 (94.9) 304 (93.3) 453 (93.8) 0.46
PASI total scorea, mean (SD) 6.3 (6.6) 6.1 (8.0) 6.2 (7.5) 0.77
cDMARD at baseline, n (%) 93 (59.2) 194 (59.5) 287 (59.4) 0.74
Methotrexate at baseline, n (%) 77 (49.0) 156 (47.9) 233 (48.2) 0.98
aFor patients with plaque psoriasis. Abbreviations, BMI = body mass index, CASPAR = classification of psoriatic arthritis; cDMARD = conventional disease-modifying
antirheumatic drug; curr. = current, MDA =minimal disease activity, NR = non-responder, N = number of patients in the analysis population, n = number of patients
in each subgroup, PASI = psoriasis area and severity index, PsA = psoriatic arthritis, −R = responder, SD = standard deviation
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a
b
Fig. 1 SF-36 domain scores at baseline and Week 24 and change from baseline and difference by MDA responder status. Data for the SF-36 domain
scores showing (a) Values at Baseline (red) and Week 24 (blue) by MDA responder status and (b) Change from baseline to Week 24 by MDA responder
status. Data labels in panel b show the difference and p-value for difference between MDA responder and non-responder groups. Note that baseline
values for all SF-36 domain scores were significantly lower for MDA non-responders versus MDA responders (data shown in Additional file 1: Table S1).
MDA =minimal disease activity; SF-36 = 36-Item Short Form Health Survey
Table 2 Efficacy data at baseline, Week 24, and change from baseline by MDA response, mean (SD)














SF-36 PCS 35.8 (9.4) 31.9 (8.9) < 0.001 48.1 (7.1) 35.0 (9.6) 12.3 (9.0) 3.1 (7.8) 9.2 (8.2) < 0.001
SF-36 MCS 49.3 (11.8) 46.8 (12.6) 0.047 53.7 (8.3) 50.5 (11.3) 4.4 (11.5) 3.8 (9.7) 0.7 (10.3) 0.51
EQ-5D-5 L HSI 0.62 (.20) 0.56 (.21) 0.003 0.82 (.14) 0.63 (0.17) 0.20 (0.20) 0.07 (0.20) 0.13 (0.20) < 0.001
EQ-5D VAS 57.5 (21.0) 53.2 (20.3) 0.040 80.0 (16.6) 58.9 (20.3) 22.5 (21.7) 5.7 (22.4) 16.8 (22.2) < 0.001
WPAI-SHP
% absenteeism 7.8 (20.4)a 6.2 (18.0)b 0.53 4.3 (15.1)a 8.2 (22.7)b −3.5 (20.5)a 2.0 (25.7)b −5.5 (23.9) 0.096
% presenteeism 33.8 (23.8)c 40.9 (25.6)d 0.061 6.8 (9.0)c 27.7 (22.0)d −27.0 (23.3)c −13.2 (27.0)d −13.74 (25.67) < 0.001
Overall work impairment 36.0 (25.7)c 42.2 (26.5)d 0.12 9.8 (13.4)c 30.2 (23.8)d −26.2 (25.2)c −12.1 (28.0)d −14.1 (27.0) < 0.001
% activity impairment non-work 42.2 (25.9)e 52.7 (24.9)f <.001 10.0 (12.0)e 37.9 (24.9)f −32.2 (26.9)e −14.9 (28.4)f −17.4 (27.9) < 0.001
Number of patients with data available where different from total n:an = 84; bn = 142; cn = 82; dn = 134; en = 152; fn = 321
Abbreviations BL = baseline, Diff. = difference, EQ-5D-5 L = European Quality of Life 5 Dimension 5 Level Health Questionnaire, HSI = Health State Index,
MCS =mental component summary, MDA =minimal disease activity, PCS = physical component summary, MDA-R =MDA-responder, MDA-NR =MDA-non-responder,
SF-36 = 36-Item Short Form Health Survey, VAS = visual analog scale,WPAI-SHP =Work Productivity and Activity Impairment–Specific Health Problem
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had better HRQoL, were younger, more likely to be male,
and had lower body mass index (BMI) compared to
non-responders. This is consistent with observations from
longitudinal studies of tumor necrosis factor inhibitors
that higher BMI is associated with a lower treatment re-
sponse [28]. Although MDA non-responders had signifi-
cantly lower HRQoL scores across measures at baseline,
their magnitude of improvement and percentage achieving
Table 3 Minimal clinically important difference in change from baseline to Week 24 by MDA responder (R) or non-responder (NR)
status
Achieved MCID Improvement MDA-R (n = 152) MDA-NR (n = 322) P-Value Ɣ-Value (ASE)a Odds Ratio (95% CIs)
SF-36 Domains
Physical functioning
Yes 124 (81.6%) 182 (56.5%) <.001 3.41
No 28 (18.4%) 140 (43.5%) .55 (.083) (2.14, 5.43)
Role physical
Yes 124 (81.6%) 175 (54.3%) <.001 3.72
No 28 (18.4%) 147 (45.7%) .58 (.079) (2.34, 5.92)
Bodily pain
Yes 130 (85.5%) 188 (58.4%) <.001 4.21
No 22 (14.5%) 134 (41.6%) .62 (.080) (2.55, 6.97)
General health
Yes 121 (79.6%) 166 (51.6%) <.001 3.67
No 31 (20.4%) 156 (48.4%) .57 (.077) (2.34, 5.76)
Vitality
Yes 118 (77.6%) 184 (57.1%) <.001 2.60
No 34 (22.4%) 138 (42.9%) .44 (.090) (1.68, 4.04)
Social functioning
Yes 95 (62.5%) 149 (46.3%) <.001 1.94
No 57 (37.5%) 173 (53.7%) .32 (.090) (1.30, 2.87)
Role emotional
Yes 66 (43.4%) 143 (44.4%) .840 .96
No 86 (56.6%) 179 (55.6%) −.02 (.099) (0.65, 1.42)
Mental health
Yes 90 (59.2%) 166 (51.6%) .118 1.36
No 62 (40.8%) 156 (48.4%) .15 (.097) (0.92, 2.02)
SF-36 PCS
Yes 130 (85.5%) 157 (48.8%) <.001 6.21
No 22 (14.5%) 165 (51.2%) .72 (.061) (3.76, 10.26)
SF-36 MCS
Yes 80 (52.6%) 160 (49.7%) .550 1.13
No 72 (47.4%) 162 (50.3%) .06 (.098) (0.76, 1.66)
EQ-5D-5 L HSI
Yes 117 (77.0%) 152 (47.2%) <.001 3.74
No 35 (23.0%) 170 (52.8%) .58 (.074) (2.42, 5.78)
EQ-5D VAS
Yes 113 (74.3%) 130 (40.4%) <.001 4.28
No 39 (25.7%) 192 (59.6%) .62 (.067) (2.79, 6.56)
aƔ-values near 1 indicate a strong association between clinical response and MDA. Abbreviations: ASE = asymptotic standard error, CIs = confidence intervals, EQ-
5D-5 L = European Quality of Life 5 Dimension 5 Level Health Questionnaire, HSI = Health State Index, MCID =minimal clinically important difference, MCS =mental
component summary, MDA =minimal disease activity, PCS = physical component summary, SF-36 = 36-Item Short Form Health Survey, VAS = visual analog scale
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MCID were lower than for MDA responders. This
indicates a need to better characterize this subset of PsA
patients who appear to have worse disease impact and to
be less responsive to treatment. Finally, although enthesitis
at baseline was associated with subsequent MDA nonre-
sponse, while baseline dactylitis was associated with subse-
quent MDA response, it is likely that these findings reflect
a relationship with the specific measures defining MDA
(which include enthesitis count and tender/swollen joint
count) rather than prediction of disease activity.
The results from these ixekizumab RCTs are sup-
ported by recent findings from small cross-sectional
studies. Patients not in MDA from the Netherlands
scored significantly worse on measures of symptoms and
functioning (BASDAI, HAQ), dermatology quality of life
index (DLQI), daily activity impairment (WPAI ADL),
and the mental and physical components of the SF-36
[29]. Queiro and colleagues assessed the association
between MDA status and PsA life impact as assessed by
the PsA Impact of Disease (PsAID) questionnaire among
Spanish patients fulfilling CASPAR criteria with
disease for at least 1 year [30]. Among the 58.6% of
patients with MDA, the impact of disease was
significantly lower based on mean PsAID score (in-
strument range 0 to 10; MDA responders 3.3 vs.
non-responders 7.1; p < .0001) and also based on the
proportion of patients in the PsAID patient acceptable
symptom state of < 4 [31] (66.7% of MDA responders
vs. 37.4% of non-responders; p < .0001).
A major strength of our study, in addition to MDA be-
ing pre-specified as a key secondary outcome in one of
the studies, was the availability of pre- and post-treatment
data, which enabled us to compare MDA responders ver-
sus non-responders in terms of the magnitude of change
during treatment, as well as the percentages of individuals
who achieved MCID in improvements from baseline. A
limitation of our study is the exclusion of patients who
were inadequate responders at Week 16 due to the study
design, which specified a potential change in therapy at
Week 16 for patients not meeting pre-defined minimal re-
sponse criteria, while MDA was assessed at baseline and
at 24 weeks. However, inadequate responders would pre-
sumably include more MDA non-responders than re-
sponders and their exclusion is most likely to lessen the
differences between groups. Another limitation is that the
analyses were performed post hoc.
Conclusions
In this study assessing both biologic naïve and experi-
enced PsA patients treated with ixekizumab in two
phase III RCTs, MDA response was found to be associ-
ated with significantly greater improvements in all SF-36
domains, the SF-36 PCS but not MCS score, and both
the EQ-5D-5 L Health State Index and VAS scores. In
addition, greater improvements in work-related func-
tioning on the WPAI were seen in MDA responders ver-
sus non-responders. These results indicate that MDA
response was strongly associated with improvements in
generic HRQoL and productivity in patients with PsA.
Taken together with previous findings showing improved
physical functioning and reduced disease progression on
MDA responders, these findings suggest that MDA re-
sponse is a strong discriminator for achieving a desirable
disease status based on both physician and patient re-
ported outcomes in PsA.
Additional file
Additional file 1: Table S1. SF-36 domain scores by MDA responder
status, mean (SD) and p-values. (DOCX 15 kb)
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RCTs: Randomized controlled trials; SF-36: Short Form Health Survey;
TICOPA: TIght COntrol of inflammation in early Psoriatic Arthritis; VAS: Visual
analogue scale; WPAI ADL: WPAI daily activity impairment; WPAI-SHP: Work
Productivity and Activity Impairment–Specific Health Problem
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